Artifacts in optical coherence tomography

Saudi Journal of Ophthalmology

Volumn 28, Issue 2, 2014, Pages 81-87

  Chhablani, Jay ^a   Krishnan, Tandava ^b   Sethi, Vaibhav ^a   Kozak, Igor ^c  

^a L V PRASAD EYE INSTITUTE   (India)

^b CARE HOSPITAL   (India)

^c KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

Artifacts; Cirrus; Optical coherence tomography; Spectral domain optical coherence tomography; Spectralis; Time domain optical coherence tomography; TOPCON

Indexed keywords

VASCULOTROPIN INHIBITOR;

ARTICLE; ARTIFACT; COMPUTER PROGRAM; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIAGNOSTIC ERROR; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PHYSICIAN; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HOLE;

EID: 84900536035     PISSN: 13194534     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjopt.2014.02.010     Document Type: Article

References (31)

1. Ho J., Sull A.C., Vuong L.N., Chen Y., Liu J., Fujimoto J.G., et al. Assessment of artifacts and reproducibility across spectral- and time-domain optical coherence tomography devices. Ophthalmology 2009, 116:1960-1970.
2. Sadda S.R., Wu Z., Walsh A.C., Richine L., Dougall J., Cortez R., et al. Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 2006, 113:285-293.
3. Ray R., Stinnett S.S., Jaffe G.J. Evaluation of image artifact produced by optical coherence tomography of retinal pathology. Am J Ophthalmol 2005, 139:18-29.
4. Ho J., Castro D.P., Castro L.C., Chen Y., Liu J., Mattox C., et al. Clinical assessment of mirror artifacts in spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2010, 51:3714-3720.
5. Mitchell P., Korobelnik J.F., Lanzetta P., Holz F.G., Prunte C., Schmidt-Erfurth U., et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010, 94:2-13.
6. Aiello L.P., Beck R.W., Bressler N.M., Browning D.J., Chalam K.V., Davis M., et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology 2011, 118:e5-e14.
7. Keane P.A., Sadda S.R. Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab. Clin Ophthalmol 2011, 5:771-781.
8. Mitry D., Bunce C., Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 2013, 1:CD009510.
9. Hee M.R. Artifacts in optical coherence tomography topographic maps. Am J Ophthalmol 2005, 139:154-155.
10. Han I.C., Jaffe G.J. Evaluation of artifacts associated with macular spectral-domain optical coherence tomography. Ophthalmology 2010, 117:1177-1189.e4.
11. Giani A., Cigada M., Choudhry N., Deiro A.P., Oldani M., Pellegrini M., et al. Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol 2010, 150:815-824.
12. Leung C.K., Cheung C.Y., Weinreb R.N., Lee G., Lin D., Pang C.P., et al. Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 2008, 49:4893-4897.
13. Forooghian F., Cukras C., Meyerle C.B., Chew E.Y., Wong W.T. Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci 2008, 49:4290-4296.
14. Mylonas G., Ahlers C., Malamos P., Golbaz I., Deak G., Schuetze C., et al. Comparison of retinal thickness measurements and segmentation performance of four different spectral and time domain OCT devices in neovascular age-related macular degeneration. Br J Ophthalmol 2009, 93:1453-1460.
15. Patel P.J., Chen F.K., da Cruz L., Tufail A. Segmentation error in Stratus optical coherence tomography for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2009, 50:399-404.
16. Sull A.C., Vuong L.N., Price L.L., Srinivasan V.J., Gorczynska I., Fujimoto J.G., et al. Comparison of spectral/Fourier domain optical coherence tomography instruments for assessment of normal macular thickness. Retina 2010, 30:235-245.
17. Campbell R.J., Coupland S.G., Buhrmann R.R., Kertes P.J. Effect of eccentric and inconsistent fixation on retinal optical coherence tomography measures. Arch Ophthalmol 2007, 125:624-627.
18. Kraus M.F., Potsaid B., Mayer M.A., Bock R., Baumann B., Liu J.J., et al. Motion correction in optical coherence tomography volumes on a per A-scan basis using orthogonal scan patterns. Biomed Opt Express 2012, 3:1182-1199.
19. Kim J.S., Ishikawa H., Sung K.R., Xu J., Wollstein G., Bilonick R.A., et al. Retinal nerve fibre layer thickness measurement reproducibility improved with spectral domain optical coherence tomography. Br J Ophthalmol 2009, 93:1057-1063.
20. Baskin D.E., Gault J.A., Vander J.F., Dugan J.D. Double fovea artifact. Ophthalmology 2011, 118:429.e1.
21. Ricco S., Chen M., Ishikawa H., Wollstein G., Schuman J. Correcting motion artifacts in retinal spectral domain optical coherence tomography via image registration. Med Image Comput Comput Assist Interv 2009, 12:100-107.
22. Hillmann D., Bonin T., Luhrs C., Franke G., Hagen-Eggert M., Koch P., et al. Common approach for compensation of axial motion artifacts in swept-source OCT and dispersion in Fourier-domain OCT. Opt Express 2012, 20:6761-6776.
23. Browning D.J., Fraser C.M., Propst B.W. The variation in optical coherence tomography-measured macular thickness in diabetic eyes without clinical macular edema. Am J Ophthalmol 2008, 145:889-893.
24. Diabetic Retinopathy Clinical Research Network, Krzystolik M.G., Strauber S.F., Aiello L.P., Beck R.W., Berger B.B., et al. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 2007, 114:1520-1525.
25. Wolf-Schnurrbusch U.E., Ceklic L., Brinkmann C.K., Iliev M.E., Frey M., Rothenbuehler S.P., et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009, 50:3432-3437.
26. Arevalo J.F., Lasave A.F., Arias J.D., Serrano M.A., Arevalo F.A. Clinical applications of optical coherence tomography in the posterior pole: the 2011 Jose Manuel Espino Lecture - Part II. Clin Ophthalmol 2013, 7:2181-2206.
27. Arevalo J.F., Lasave A.F., Arias J.D., Serrano M.A., Arevalo F.A. Clinical applications of optical coherence tomography in the posterior pole: the 2011 Jose Manuel Espino Lecture - Part I. Clin Ophthalmol 2013, 7:2165-2179.
28. Fung A.E., Lalwani G.A., Rosenfeld P.J., Dubovy S.R., Michels S., Feuer W.J., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007, 143:566-583.
29. Lalwani G.A., Rosenfeld P.J., Fung A.E., Dubovy S.R., Michels S., Feuer W., et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009, 148:43-58.e1.
30. Karam E.Z., Ramirez E., Arreaza P.L., Morales-Stopello J. Optical coherence tomographic artefacts in diseases of the retinal pigment epithelium. Br J Ophthalmol 2007, 91:1139-1142.
31. Kim M., Lee S.J., Han J., Yu S.Y., Kwak H.W. Segmentation error and macular thickness measurements obtained with spectral-domain optical coherence tomography devices in neovascular age-related macular degeneration. Ind J Ophthalmol 2013.